Theresa Simon
Internal Medicine · Point Pleasant, WVNPI 1356423016
Payments from drug & device makers
Across 129 payments — averaging $17.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- GSK$213
- Lilly USA, LLC$159
- Astellas Pharma US Inc$119
- Pfizer$90
- Novartis$71
- plus $393 from 12 others
What the payments were for
- Food & beverage$2,310100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 67 | $1,265 |
| GSK | 13 | $213 |
| Lilly USA, LLC | 10 | $159 |
| Astellas Pharma US Inc | 6 | $119 |
| Pfizer | 6 | $90 |
| Novartis | 5 | $71 |
| Johnson & Johnson | 3 | $65 |
| Novo Nordisk | 4 | $60 |
| Merck | 3 | $55 |
| E.r. Squibb & Sons, L.L.C. | 3 | $43 |
| Boehringer Ingelheim | 2 | $33 |
| Inspire Medical Systems, Inc. | 1 | $28 |
| Otsuka America Pharmaceutical, Inc. | 1 | $22 |
| Abbott | 1 | $21 |
| Bayer | 1 | $18 |
| Amarin Pharma, Inc. | 1 | $17 |
| Amgen | 1 | $15 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
How this compares
$2,310 in reported general payments places this provider in the 80th percentile of 573 internal medicine providers in West Virginia.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 110 | $134,873 |
| EliquisApixaban | 107 | $123,335 |
| OzempicSemaglutide | 115 | $115,350 |
| MounjaroTirzepatide | 71 | $93,768 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 75 | $72,706 |
| FarxigaDapagliflozin Propanediol | 25 | $31,013 |
| JanuviaSitagliptin Phosphate | 19 | $29,787 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 68 | $14,805 |
| XareltoRivaroxaban | 12 | $14,049 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 12 | $12,104 |
| Spiriva HandihalerTiotropium Bromide | 15 | $11,365 |
| Breo ElliptaFluticasone/Vilanterol | 17 | $9,191 |
| Tresiba Flextouch U-100Insulin Degludec | 11 | $8,468 |
| Novolog FlexpenInsulin Aspart | 38 | $7,856 |
| Ezetimibe | 221 | $6,987 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Spiriva Respimat | $33 | $141,053122 claims |
| PfizerEliquis | $90 | $123,335107 claims |
| Novo NordiskOzempic | $60 | $115,350115 claims |
| Lilly USA, LLCMounjaro | $159 | $93,76871 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta | $213 | $87,142103 claims |
| MerckJanuvia | $55 | $29,78719 claims |
| Johnson & JohnsonXarelto | $65 | $14,04912 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 573 internal medicine providers in West Virginia.
Other internal medicine in Point Pleasant
- Randall HawkinsPoint Pleasant$6K
- Ward PaineMorgantown$5.1M
- William ChapmanCharleston$1.7M
- Mustafa AwiliHuntington$906K
- David PickeringParkersburg$694K
- Laura DavissonMorgantown$118K
- Michael BrumageClendenin$87K
- Govind PatelFairmont$59K
- Lynn SmithLewisburg$31K
- Bisher MustafaHuntington$28K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.